Newly FDA-Cleared Stereotactic System Can be Utilized with Pre-Op MRI or CT
Utilized for neurological procedures including biopsies, catheter placement and electrode introduction, the SmartFrame OR Stereotactic System can be combined with preoperative MRI or CT to ensure optimal placement of devices and instruments.
The Food and Drug Adminstration (FDA) has granted 510(k) clearance for the SmartFrame OR Stereotactic System, which reportedly facilitates optimal preoperative placement of instruments and devices for neurological procedures.
Comprised of the SmartFrame OR and the ClearPointer™ Optical Navigation Wand, the SmartFrame OR Stereotactic System can enhance preoperative planning for electrode introduction, catheter placement and brain biopsy procedures, according to ClearPoint Neuro, the manufacturer of the system. The company noted the SmartFrame OR can be combined with preoperative magnetic resonance imaging (MRI) or computed tomography (CT).
Utilized in combination with the SmartFrame OR and a compatible stereotactic optical navigation system, the ClearPointer Optical Navigation Wand facilitates patient registration and navigation, according to ClearPoint Neuro.
“SmartFrame OR embodies over a decade of accumulated expertise in MRI-guided navigation, now enhanced with the latest OR imaging technology,” said Rob Rubio, a segment leader for neuromodulation at ClearPoint Neuro. “It offers surgeons flexible workflows, including iCT forward projection, enabling precise image-based corrections to achieve sub-millimetric accuracy.”
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
